BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 9477948)

  • 21. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
    Sui GC; Wiman B
    Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
    Audenaert AM; Knockaert I; Collen D; Declerck PJ
    J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
    Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
    Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular variant of plasminogen activator inhibitor of rat decidual tissue.
    Tarachand U; Pawse AR
    Biochem Mol Biol Int; 1995 Dec; 37(6):1037-45. PubMed ID: 8747533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
    Padmanabhan J; Sane DC
    Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
    Vleugels N; Leys J; Knockaert I; Declerck PJ
    Thromb Haemost; 2000 Nov; 84(5):871-5. PubMed ID: 11127870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
    Royle G; Deng G; Seiffert D; Loskutoff DJ
    Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis of latency in plasminogen activator inhibitor-1.
    Mottonen J; Strand A; Symersky J; Sweet RM; Danley DE; Geoghegan KF; Gerard RD; Goldsmith EJ
    Nature; 1992 Jan; 355(6357):270-3. PubMed ID: 1731226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
    J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serpin-resistant mutants of human tissue-type plasminogen activator.
    Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
    Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model of the reactive form of plasminogen activator inhibitor-1.
    Aertgeerts K; De Bondt HL; De Ranter C; Declerck PJ
    J Struct Biol; 1994; 113(3):239-45. PubMed ID: 7734247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibitor expression in cultured murine keratinocytes.
    Bator JM; Cohen RL; Chambers DA
    Exp Cell Res; 1998 Jul; 242(1):110-9. PubMed ID: 9665808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
    Vleugels N; Leys J; Knockaert I; Declerck PJ
    J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction, expression and characterization of tissue-type plasminogen activator mutants.
    Liu S; Huang P; Huang C
    Sci China B; 1995 Nov; 38(11):1341-8. PubMed ID: 8745532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
    van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
    FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
    Urano T; Wu K; Ihara H; Takada Y; Takada A
    Pol J Pharmacol; 1996; 48(2):209-13. PubMed ID: 9112653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of tissue-type plasminogen activator and its inhibitor (PAI-1) by lipopolysaccharide-induced phagocytosis in a Sertoli cell line.
    Bourdon V; Defamie N; Fenichel P; Pointis G
    Exp Cell Res; 1999 Mar; 247(2):367-72. PubMed ID: 10066364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.